Loading clinical trials...
Loading clinical trials...
Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Conditions
Interventions
E7016 + TMZ
Locations
5
United States
Boston, Massachusetts, United States
Lebanon, New Hampshire, United States
Greenville, South Carolina, United States
San Antonio, Texas, United States
Charlottesville, Virginia, United States
Start Date
March 29, 2010
Primary Completion Date
February 24, 2011
Completion Date
February 24, 2011
Last Updated
October 10, 2024
NCT07489378
NCT07181681
NCT07204340
NCT07403721
NCT07395258
NCT06885281
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions